首页> 美国卫生研究院文献>Mediators of Inflammation >Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
【2h】

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells

机译:程序性死亡1和程序性死亡配体1的高表达负面调节针对宫颈癌细胞的免疫反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The present study is to measure the expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), as well as its clinical significance in cervical cancer patients. Our results showed that different T cell subsets in patients with cervical cancer had high expression of PD-1, and DCs had high expression of PD-L1. High expression of PD-1 on Treg cells in cervical cancer patients facilitated the production of TGF-β and IL-10 but inhibited the production of IFN-γ. Cervical cancer elevated the expression of PD-1 and PD-L1 in mRNA level. PD-1 expression in peripheral blood of cervical cancer patients was related with tumor differentiation, lymph node metastasis, and invasiveness. PD-1/PD-L1 pathway inhibited lymphocyte proliferation but enhanced the secretion of IL-10 and TGF-β in vitro. In summary, our findings demonstrate that elevated levels of PD-1/PD-L1, TGF-β, and IL-10 in peripheral blood of cervical cancer patients may negatively regulate immune response against cervical cancer cells and contribute to the progression of cervical cancer. Therefore, PD-1/PD-L1 pathway may become an immunotherapy target in the future.
机译:本研究旨在测量程序性死亡-1(PD-1)和程序性死亡配体-1(PD-L1)的表达及其在宫颈癌患者中的临床意义。我们的结果表明,子宫颈癌患者中不同的T细胞亚群高表达PD-1,而DC则高表达PD-L1。宫颈癌患者Treg细胞上PD-1的高表达促进了TGF-β和IL-10的产生,但抑制了IFN-γ的产生。宫颈癌在mRNA水平上升高了PD-1和PD-L1的表达。宫颈癌患者外周血中PD-1的表达与肿瘤的分化,淋巴结转移和侵袭性有关。 PD-1 / PD-L1途径可抑制淋巴细胞增殖,但在体外可增强IL-10和TGF-β的分泌。总而言之,我们的研究结果表明宫颈癌患者外周血中PD-1 / PD-L1,TGF-β和IL-10的升高水平可能会负面调节针对宫颈癌细胞的免疫反应,并有助于宫颈癌的发展。因此,PD-1 / PD-L1途径可能成为未来的免疫治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号